Michael C. Creedon Jr. has been appointed interim CEO upon Rick Dreiling's stepping down as chairman and CEO, effective Nov. 3 due to health challenges.
Orlynvah is used to treat uncomplicated urinary tract infections caused by certain microorganisms in adult women who have limited or no alternative oral antibacterial treatment options.